Myriad Genetics raises full-year forecast on Crescendo buy

Tue Feb 4, 2014 5:04pm EST

Feb 4 (Reuters) - Molecular diagnostics company Myriad Genetics Inc said it plans to buy Crescendo Bioscience for $270 million to enter the autoimmune market, and raised its full-year forecast.

Myriad Genetics, whose shares rose about 16 percent in extended trading, said it expects earnings of $2.09-$2.12 per share on revenue of $740-$750 million in the year ending June 30.

It had earlier forecast $1.92-$1.97 per share on revenue of $700-$715 million.

Myriad also reported a better-than-expected profit for the second quarter, helped by higher sales of its breast and ovarian cancer detection tests.

Net income rose to $50.4 million, or 66 cents per share, in the quarter ended Dec. 31, from $35.0 million, or 42 cents per share, a year earlier.

Revenue rose 37 percent to $204.0 million.

Analysts on average had expected earnings of 46 cents on revenue of $176.0 million, according to Thomson Reuters I/B/E/S.

Myriad shares closed at $27.18 Tuesday on the Nasdaq.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (2)
jgtexas wrote:
At First Financial Advisors, we are bullish on MYGN.

http://www.yoursmartmoney.net/welcome.html

Feb 07, 2014 1:15am EST  --  Report as abuse
jgtexas wrote:
At First Financial Advisors, we are bullish on MYGN.

http://www.yoursmartmoney.net/welcome.html

Feb 07, 2014 1:15am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.